Marksans Pharma Share Price Gains Over 13% After Q1 FY27 Earnings Results: Total Income Up 38.5% YoY

On August 12, 2026, Marksans Pharma Limited released its consolidated unaudited financial results for the quarter ending June 30, 2026, as per the exchange filings.  

The reported data highlights the company performance metrics in comparison to the previous year and the preceding quarter. 

Marksans Pharma Q1 FY27 Earnings Results 

In the quarter ended June 30, 2026, Marksans Pharma Limited achieved a total income of ₹866.20 crore. This figure represents an increase of 38.5% compared to the ₹625.63 crore recorded in the same quarter of the previous year.  

When assessed on a quarter-on-quarter basis, the total income experienced a decrease of 2.8% from the ₹891.29 crore reported in the quarter ended March 31, 2026. 

The net profit, referred to as Profit After Tax, reached ₹159.41 crore for the quarter ended June 30, 2026. This reflects a growth of 173.9% in comparison to the ₹58.20 crore profit reported for the quarter ended June 30, 2025.  

Additionally, the net profit showed an increase of 7.0% from the ₹149.03 crore profit recorded in the March 2026 quarter. 

Annual Performance for FY26 

For the financial year 2026, the company recorded a total income of ₹3,033.47 crore. The net profit for the same financial year was reported at ₹420.06 crore. These figures represent the consolidated financial standing of the entity for the specified annual period. 

Profitability and Cash Balances 

The company registered an all-time high quarterly EBITDA of ₹213 crore, climbing 112.8 percent year-on-year. Net profit after tax expanded by 173.9 percent to reach ₹159 crore. 

The corporate cash balance crossed a critical milestone to reach ₹1,058 crore. This happened despite recent major capital allocations for geographic expansion and strategic acquisitions. 

Western Market Performance 

The United States and North America formulation segment recorded revenues of ₹377 crore. This division remains the largest contributor, making up approximately 45 percent of consolidated earnings. 

The United Kingdom and Europe formulation business delivered a record revenue of ₹356 crore. Regional growth was accelerated by the newly completed acquisition of European entity QliniQ. 

Other Regional Segments 

The Australia and New Zealand operations reported revenues of ₹88 crore. This represents a 53.7 percent year-on-year surge driven by successful portfolio expansion and new product introductions. 

Rest of World business generated revenues of ₹20 crore, falling 36.8 percent year-on-year. However, the segment showed a 6.0 percent sequential expansion, marking its first improvement in four quarters. 

Operational Cash Flow 

The pharmaceutical enterprise generated robust cash flow from operations amounting to ₹185 crore. Net capital expenditure incurred during the three-month period stood at ₹33 crore. 

Free cash flow concluded at ₹152 crore for the quarter. Additionally, the operational working capital cycle improved from 159 days down to 132 days year-on-year. 

R&D and Strategic Ratings 

Research and development expenditure reached ₹23 crore during the June 2026 quarter. This specialized investment represents approximately 2.8 percent of the consolidated operational revenue. 

India Ratings and Research revised the bank facility outlook to Positive from Stable. Meanwhile, the leading agency affirmed the short-term and long-term credit ratings at IND AA- and IND A1+. 

Read More: Samvardhana Motherson Share Price Hit Record High After Q1 FY27 Results! 

Marksans Pharma Share Price Performance 

As of August 12, 2026, at 1:35 PM, Marksans Pharma share price on NSE was trading at ₹315.85, up by 13.23% from the previous closing price. 

Conclusion 

Marksans Pharma Limited recorded a total income of ₹866.20 crore and a net profit of ₹159.41 crore for the quarter ended June 30, 2026. FY26 figures included a total income of ₹3,033.47 crore and ₹420.06 crore profit. 

Disclaimer: This blog has been written exclusively for educational purposes. The securities or companies mentioned are only examples and not recommendations. This does not constitute a personal recommendation or investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.